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Abstract Head and neck squamous cell carcinomas (HNSC
C) show diverse clinicopathological features and are mostly
linked with poor outcome. In this study, we tested if the
expression of tumor growth, cell cycle and basement mem-
brane anchorage related biomarkers allow prognostic and
clinicopathological stratification of HNSCC. Archived
HNSCC samples from 226 patients included into tissue mi-
croarrays (TMA) were tested using immunohistochemistry.
Histopathological evaluation and the analysis of immuno-
staining for EGFR, Ki67, p53, p16ink4 and Collagen XVII
proteins were carried out in digital whole slides. Statistical
evaluation was carried out using Pearson’s Chi-square test and
Kaplan-Meier survival analysis. In the tested cohort,
hypopharyngeal cancers had the least favorable, and glottic
cancers had the most favorable prognosis. High Ki67 positive
tumor cell fractions were associated with significantly worse
prognosis and elevated rate of lymph node metastasis. Both
Ki67 and EGFR expression correlated significantly with the
tumor localization. Ki67 index was the highest in the
hypopharyngeal region and it proved to be the lowest in the
glottic region. EGFR expression was the highest in the oral
cavity and the lowest in the glottic region. The survival rate of
patients with p16ink4-negative cancer was significantly lower
than of those with p16ink4-positive disease. A significant
inverse correlation was found between histological grade
and the prognosis of HNSCC. Our data support that elevated
Ki67 positive proliferating cell fractions contribute to the
unfavorable prognosis of hypopharyngeal cancers, while
glottic cancers have the most favorable prognosis because of
the lowest Ki67 expression rate.
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Introduction
Every year, about half a million cases of new head and neck
cancers are diagnosed worldwide with the vast majority of
them are known to be squamous cell carcinomas [1]. Since
head and neck squamous cell carcinomas (HNSCC) include a
wide range of carcinomas into the same histopathological
entity, members of this group may show variable clinicopath-
ological features. The vast majority of HNSCC patients pres-
ent with advanced diseases [2]. Stage III-IVb diseases usually
require combination therapy (e.g. induction chemotherapy
followed by chemoradiation), while biological therapy is re-
served for metastatic and/or recurrent head and neck cancers
[3]. The current biological- (cetuximab) and chemotherapeutic
regimens (platinum based agents, 5-fluorouracil, taxanes) are
rather toxic, and only a portion of the treated tumors show
remission.
In the daily clinical practice, the TNM classification is used
for selecting the most suitable therapeutic option. Among
clinical parameters, age does not affect survival [4]. However,
the prognostic role of histological grade is not well established
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in head and neck carcinomas [5]. The clinical outcome of
HNSCC can differ according to anatomical localization.
Glottic malignancies show the best and hypopharyngeal can-
cers the worst prognosis [2].
The fact that the mean survival of HNSCC patients is
considerably poor with only ~50 % of 5-year overall survival
[2], urges investigations for finding novel prognostic markers
and predictivemarkers that may support therapeutic decisions.
Previously identified biomarkers can help to predict prog-
nosis of HNSCCs, however their clinical application is limit-
ed, currently, there is no evidence-based recommendation for
altering the treatment of patients with HNSCCs on the basis of
the expression of certain biomarkers [6].
Human Papillomavirus (HPV) has been recently raised as a
driver of HNSCC development [7] suggesting that more than
a half of tonsillar cancers are related to HPV [7]. This subset of
HNSCC, however, showed better prognosis than cancers
caused by tobacco and alcohol consumption [8]. The gold
standard for evaluating HPV status is the detection of HPV
E6/7 mRNA expression. However, it has been published that
detecting tumor p16-expression by immunohistochemistry
can be a surrogate marker with 100 % sensitivity and 80 %
specificity [9]. The growth factor receptor EGFR is known to
be overexpressed in 80–90 % of HNSCCs, and to be associ-
ated with poor survival, nevertheless it cannot be used as a
predictor of response rate to cetuximab therapy [10].
By studying the expression of type I epidermal growth
factor receptor (EGFR), the hemidesomosal adhesion mole-
cule collagen XVII and the cell replication related proteins
p53, p16ink4, Ki67, we have earlier provided evidence on the
differential biomarker expression in HNSCC according to
anatomical localization [11]. In this study, we correlated the
expression of these biomarkers with further clinicopathologi-
cal features including disease prognosis in a larger HNSCC
patient cohort.
Materials and Methods
Patients
HNSCC samples from 226 patients (177 men, 49 women;
mean age: 58 years [36–89]) enrolled in this study were
collected from the archives of Jahn Ferenc South-Pest Hospi-
tal, Budapest, Hungary between 2000 and 2008. Patients with
rare cancer types (e.g. salivary gland tumors, nasopharyngeal
carcinoma, sinonasal tumors and sarcomas) were excluded
from the analysis because of their special clinical and mor-
phological characteristics. The tested lesions included cancers
of the oral cavity - 12 cases (body of tongue, floor of mouth);
oropharynx— 69 cases (18 palatine tonsil, 12 base of tongue,
5 tonsilo-lingual, 3 tonsillar fossa, 8 soft palate, 23 other part
of oropharynx); hypopharynx— 43 cases; larynx— 102 cases
(42 supraglottic, 43 glottic, 17 transglottic) (Table 1.).
Tissue Microarray (TMA) and Immunohistochemistry
Using the computer controlled TMA Master (3DHISTECH
Kft., Budapest, Hungary), we created 8 TMA blocks contain-
ing duplicate cores of 2 mm diameter from formalin-fixed,
paraffin-embedded tumor samples of the 226 HNSCC pa-
tients. Seven blocks contained 70 samples each and one
contained 20 samples making up 510 cores for each staining.
Immunohistochemistry was performed in 4 μm thick serial
TMA sections following routine dewaxing, rehydration and
blocking of endogeneous peroxidase activity using 3 %
hydrogene peroxide in ethanol for 15min. For antigen retrieval,
the samples were boiled in Tris-EDTA buffer (pH: 9.0) for
25 min. For immunodetection, the NovoLink-peroxidase poly-
mer kit (Leica-NovoCastra, Newcastly-Upon Tyne, UK) was
used. Immunostaining included the following sequential incu-
bation steps using: 5 % BSA in 0.1 M Tris-buffered saline
pH 7.4 (TBS) as a protein block, for 20 min; the optimally
diluted primary antibodies (p53 – Novocastra, 1:400; p16ink4 –
LabVision-Thermo, 1:400; EGFR – Ventana-Roche, 1:1; Ki67
– DAKO, 1:1; collagen XVII, clone: 9G2, 1:200 – proprietary
[12], overnight (16 h); the post-primary reagent for 30 min.,
and the NovoLink-peroxidase polymer peroxidase complex for
30 min. Samples were washed after each incubation step 2×
5 min in TBS. Peroxidase activity was visualized using DAB/
H2O2 for 5–10 min under microscopic control. Finally, nuclear
counterstaining was applied using hematoxylin-eosin. All in-
cubations were performed in humidity chambers at room tem-
perature. Immunostained slides were digitalized using a
Pannoramic Scan instrument (3DHISTECH, Budapest, Hun-
gary). The histological evaluation and the scoring of
immunoreactions were done by three independent assessors
using the Pannoramic Viewer software (Fig. 1.).
Table 1 Anatomical distribution of the analyzed tumors
Localization No. %
Oral cavity Tongue + sublingual region 12 5.3 %
Oropharynx Soft Palate 8 3.5 %
Oropharynx (other) 23 10.2 %
Palatine tonsil 21 9.2 %
Lingual tonsil 12 5.3 %
Tonsillo-lingual 5 2.2 %
Total: 69 30.6 %
Hypopharynx 43 19.0 %
Larynx Supraglottic 42 18.5 %
Glottic 43 19.0 %
Transglottic 17 7.6 %
Total: 102 45.1 %
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Immunostained TMA spots were analyzed with the
database-linked TMA Modul software (3DHISTECH). At
least 3 tumor nests of >200 cells were considered for scoring
in each sample. Scoring criteria were as follows: Score 0:
<5 % weak staining; score 1: >5–25 % positive tumor cells,
score 2: 25–50 % positive tumor cells; and score 3: >50 %
positive tumor cells. For statistical analysis scores were di-
chotomized along different thresholds. The most reproducible
threshold for all assessors was set upwhen scores 0 and 1 were
considered negative, while scores 2 and 3 as positive.
Statistical Analysis
Kaplan - Meier survival analyses were performed followed by
Wilcoxon-Breslow tests for evaluating statistical difference in
survival between groups The primary variables concerning
survival were censored: patients with tumor-related death and
patients having cancer at the time of last visit were considered
dead, whereas tumor-free patients and those who died because
of an intercurrent disease were considered alive.
Pearson’s Chi-square tests were used for the analysis of the
correlation between biomarker positivity and tumor localization.
Statistical analysis was carried out using the package of
BMDP Statistical Software, Inc. (Los Angeles, California,
USA), and significant difference was declared when the p
value was <0.05.
Results
Survival Analysis
We found statistically significant differences between sur-
vivals according to stage, the mean survival times were as
follows: stage I - 112.9 months (Standard Error - S.E.:
13.481), stage II - 62.9 months (S.E.: 8.293), stage III -
44.65 months (S.E.: 6.671) and stage IV - 22.76 months
(S.E.: 2.531), p=0.0000 (Fig. 2.).
We also revealed significant differences between progno-
ses of diseases at different histological grade: grade I –
96.30 months (S.E.: 11.352), grade II – 41.58 (S.E.: 4.252)
and grade III – 24.66 (S.E.: 4.546), p=0.0001 (Fig. 3.).
Fig. 1 Immunohistochemical staining: a: EGFR-positive oral cancer; b:
Ki67-positive supraglottic cancer; c: p53-positive glottic cancer; d:
p16ink4-positive tonsillar cancer; e: Coll.XVII-positive hypopharyngeal
cancer; f: p16ink4-negative glottic cancer
Fig. 2 Survivals according to
tumor stage (p=0.0000)
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Comparing the patients‘survivals according to the locali-
zations of their malignancy, we found that patients with glottic
cancers had the best (avg. survival time: 77.08 months S.E.:
7.211), and patients having hypopharyngeal tumors had the
worst survival rates (avg. survival time: 20.37 months S.E.:
3.444), p=0.0000 (Fig. 4.).
From among the analyzed biomarkers, p16ink4 and Ki67
correlated significantly with the prognosis. Patients with
p16ink4-positive disease had higher survival rates than those
with p16-negative cancer (median survival time: 55 vs.
20 months, p=0.0049) (Fig. 5.). Ki67-positivity correlated
negatively to survival, patients with a Ki67-negative disease
had better prognosis (median survival time: 20 vs. 27 months,
p=0.0243) (Fig. 6.). Ki67-positivity was also associated with
a higher nodal (N) stage (p=0.0067) (Table 2.).
Regarding the 43 patients having hypopharyngeal cancers,
only 3 patients had Ki67-negative disease, and their mean
survival was higher than those having Ki67-positive tumor
(19.3 vs. 14 months).
As for the other biomarkers analyzed (EGFR, CollXVII,
p53), there was no significant correlation either with survival,
or with any clinical parameter.
Survival parameters by gender and age did not show signif-
icant differences (p=0.4210 and 0.844, respectively). In addi-
tion: there was no significant correlation between age and
tumor stage or nodal status (p=0.528 and 0.106, respectively).
Fig. 3 Survivals according to
histological grade (p=0.0001)
Fig. 4 Survivals according to
tumor site (p=0.0000)
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Correlations Between Biomarker Expression and Anatomical
Localization
Among the differences in biomarker expressions of the eval-
uated head and neck cancers, Ki67 and EGFR proved to be
significant (Table 3.).
Ki67-positivity was detected: hypopharynx: 93.0 %,
supraglottis: 85,4 %, transglottic cancers: 76.5 %, oropharynx:
75.4 %, oral cavity 58.3 %, and glottis: 40.5 % (p=0.0000).
EGFR-positivity was as follows: oral cavity 100 %,
supraglottis: 95.1 %, hypopharynx: 88.4 %, oropharynx:
78.3 %, transglottic tumors: 76.5 % and glottic tumors:
73.2 % (p=0.0317). In this setting, the other analyzed bio-
markers did not show significant regional pattern.
Then we compared the biomarker expressions according
to a functional classification. This concept was mainly
based on the distinct developmental routes followed by the
subregions.
We took the tonsillar tumors (tumors of the palatine tonsil,
tonsillo-lingual region, and base of the tongue,) together, and
compared them to the other oropharyngeal and oral cancers, in
order to compare the frequency of positive cases between
these groups (Table 4). In this case, Ki67-positivity of the
tonsillar group was significantly higher than that of the other
oropharyngeal and oral tumors (84.2 vs. 60.0 %, p=0.0406).
The p16ink4-positivity of tonsillar tumors (42.1 %) was
higher than that of the oral cavity + other oropharynx
(25.0 %), but the difference was not significant (p=0.1976).
Fig. 5 Survivals according to
p16ink4-positivity (p=0.0049)
Fig. 6 Survivals according to
Ki67-positivity (p=0.0243)
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We did not reveal any significant differences in this arrange-
ment regarding p53, EGFR and Collagen XVII expression.
Cancers of supraglottic area were also separated from those
affecting other laryngeal regions (glottic and transglottic) (Ta-
ble 5.). The ratio of Ki67 (85.4 vs. 50.8 %, p=0.00037) and
EGFR (95.1 vs. 74.1 %, p=0.0063) positive tumors were
significantly higher in the supraglottic group. The p16ink4
positivity of supraglottic tumors was also higher than the
positivity of other laryngeal tumors, but this phenomenon
did not reach the significancy level (52.5 vs. 33.3 %, p=
0.056). Neither the p53-positive nor the Collagen XVII pos-
itive HNSCCs showed significant regional difference.
Discussion
In this study, our testing for potential prognostic biomarkers in
HNSSC revealed that proliferating cell fractions significantly
correlated with tumor prognosis. In particular, elevated num-
ber of Ki67 positive cells in hypopharyngeal cancers was in
line with the worst prognostic outcome, while the lowest
frequency of Ki67 positive cells in glottic cancers was asso-
ciated with the best survival. Since, general proliferation
markers as Ki67 may not detect cell fractions, which become
arrested during the cell cycle, further studies using post-G1
phase and M-phase markers still needed to corroborate the
prognostic role of proliferation in all subtypes of HNSSC.
Head and neck cancers cannot be regarded as a homoge-
neous entity, their clinical outcome can differ substantially
according to their localization [2]. On one hand, this feature
probably stems from the differing tissue constituents (mem-
branes, ligaments, cartilages) surrounding the different head-
neck mucosal regions that may restrict the migration, spread
and lymphatic drainage of cancer cells [13].
Here, by using a larger patient cohort we confirmed our
earlier finding on the differential expression of the biomarkers
according to the anatomical regions within the head and neck
area [11]. Besides its statistical links with sub-regional and
prognostic features in HNSSC Ki67-positivity also showed
significant positive correlation with poor survival in the whole
patient cohort and was associated with higher nodal (N) stage.
The TNM classification staging is perhaps the most impor-
tant among clinical parameters that can predict the outcome of
HNSCC [14]. TNM is simple, easy-to-use, and acceptedworld-
wide. However, there can be significant inter-laboratory differ-
ences in the way TNM is used for HNSCC due to the varying
diagnostic tools used. Another disadvantage of TNM categori-
zation is that it does not take such important factors into
consideration as co-morbidity, whichwould be useful for tumor
staging [14]. In this study, we found significant inverse corre-
lation between tumor stage and disease outcome, advanced
disease was linked with poor survival.
Histological grading reflects tumor cell dedifferentiation.
Several studies have suggested histological grade as a prog-
nostic factor HNSCC; patients with high grade disease show
poor survival rates [15]. Regarding the early-stage tongue
cancers, however, not the grading, but the thickness of the
lesion was of primary prognostic importance [16]. Here, we
found significant inverse correlation between the histological
grade of HNSCC and prognosis: patients with a grade I tumor
had significantly better survival rates than those with grade III
disease.
Table 2 Ki67-positivity ratio according to nodal (N) stage (p=0.0067)
N0 N1 N2 N3
Ki67–negative 37.8 % 25 % 14.5 % 10 %
Ki67–positive 62.2 % 75 % 85.5 % 90 %
Table 3 Biomarker positivity
ratio according to anatomical
localizations
p16 pos. Ki67 pos. p53 pos. Coll XVII
pos.
EGFR pos.
Cavum oris n=12 25 % 58.3 % 50 % 91.7 % 100 %
Oropharynx n=69 36.2 % 75.4 % 48.5 % 73.5 % 78.3 %
Hypopharynx n=43 23.3 % 93 % 58.1 % 90.7 % 88.4 %
Larynx n=102 Supraglottic n=42 52.5 % 85.4 % 57.5 % 85.4 % 95.1 %
Glottic n=43 34.9 % 40.5 % 54.8 % 81.4 % 73.2 %
Transglottic n=17 29.4 % 76.5 % 46.7 % 70.6 % 76.5 %
p-value 0.119 0.000 0.8937 0.170 0.0317
Table 4 Biomarker positivity ratio according to sub-localizations
p16
pos.
Ki67
pos.
p53
pos.
Coll XVII
pos.
EGFR
pos.
Tonsils
(lingual + palatine)
n=38
42.1 % 84.2 % 44.7 % 84.2 % 86.8 %
Non-tonsillar
oropharynx +
cavum oris n=20
25 % 60 % 52.6 % 80 % 90 %
p-value 0.197 0.040 0.573 0.686 0.725
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p16ink4 inhibits cyclin dependent kinase (cdk) 4/6, which
prevents the formation of the active cyclin D-cdk4/6 complex
and early cell cycle progression. The lack of cyclin D medi-
ated phosphorylation of the retinoblastoma (Rb) protein re-
sults in the inactivation of the cell cycle in phase G1 [17].
Several reports suggest that reduced expression or the lack of
p16ink4 protein correlates with poor prognosis of HNSCC [18,
19], which we confirmed in our tested patient cohort. Recent
reports have revealed that p16ink4-expression is associated
with HPV-positivity, implying that p16ink4 can be a surrogate
marker for HPV detection.
Ki67 is a protein with unclarified functions, which can be
detected in proliferating cells throughout the cell cycle (G1, S,
G2 and M phases) but it is absent in resting (phase G0) cells.
Therefore, Ki67 as a marker of tumor growth fraction, can
carry important information about tumor agressiveness and
therapeutic response [20–22]. Despite some groups could not
confirm the prognostic role of Ki67 expression [23], in this
study we found clear negative correlation between Ki67 pos-
itive cell fractions and overall survival and a positive link with
higher nodal (N) stage. Our results showing differential ex-
pression of Ki67 in hypopharyngeal (93.0 %) compared to
glottic (40.5 %) cancers are in line with the clinical observa-
tion, that patients with glottic cancers have better life expec-
tancy and ear l ier symptoms than of those with
hypopharyngeal cancers [24]. Ki67 index may also allow
prospect ive prognost ic s t ra t i f ica t ion wi thin the
hypopharyngeal group since the 3 Ki67 negative cases
showed improved survival (19.3 vs. 14 months) compared to
the Ki67 positive cases. This, however, needs further clarifi-
cation in larger patient cohort. The frequency of Ki67-positive
tumors was also significantly higher in the tonsillar group
compared to the other oropharyngeal and oral malignancies.
Collagen XVII protein contributes to the hemidesmosomal
adhesion of basal undifferentiated keratinocytes in stratified
squamous epithelia [25]. In line with maturation,
keratinocytes lose their collagen XVII expression, however,
it can be detected as an early marker of malignant transforma-
tion in epidermal squamous cell carcinomas [26]. Apart from
detecting collagen XVII in early in situ HNSCC, no signifi-
cant difference in collagen XVII expression was noted in
relation to any clinicopathological variable tested.
P53, known as the guardian of the genome, is one of the
most commonly mutated tumor suppressor genes in human
malignancies, thus, mutation of the p53 gene is common in
head and neck cancers, too [27]. The prognostic role of p53 in
head and neck cancers is controversial [28]. Some authors
found negative correlation between p53 expression and prog-
nosis [29], while others including this study could not prove
this finding [30, 31].
Overexpression of epidermal growth factor receptor
(EGFR) can be detected in more than 80–90 % of HNSCC
[32] either with or without gene amplification, and have been
shown as a marker of poor prognosis [33, 34]. In our cohort,
EGFR levels showed regional preference in HNSCC with the
highest EGFR expression in oral cancers and the lowest in
glottic cancers.
In conclusion, based on their biomarker expression profiles
clinicopathologically relevant subgroups can be distinguished
within the heterogeneous HNSCC group. The expression of
Ki67 and EGFR show regional preference. Elevated Ki67-
positive cell fractions, reduced p16ink4 expression and high
histological grade can be linked with poor prognosis of HNSC
C. Therefore, supplementing conventional prognostic factors
with a restricted biomarker profiling can assist in prognostic
subtyping of HNSCC and may help designing a more efficient
therapy.
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